Luminopia, Inc., Cambridge, MA, 02139, USA.
Massachusetts Institute of Technology, Department of Brain and Cognitive Sciences, Picower Institute for Learning and Memory, Cambridge, MA, 02139, USA.
Sci Rep. 2020 May 20;10(1):8328. doi: 10.1038/s41598-020-65234-3.
Given the prevalence of poor adherence to therapy and the biases of self-reporting across healthcare, we hypothesized that an engaging, personalized therapy may improve adherence and treatment outcomes in the home. We tested this hypothesis in the initial indication of amblyopia, a neurodevelopmental disorder for which available treatments are limited by low adherence. We designed a novel digital therapeutic that modifies patient-selected cinematic content in real-time into therapeutic visual input, while objectively monitoring adherence. The therapeutic design integrated a custom-designed headset that delivers precise visual input to each eye, computational algorithms that apply real-time therapeutic modifications to source content, a cloud-based content management system that enables treatment in the home, and a broad library of licensed content. In a proof-of-concept human study on the therapeutic, we found that amblyopic eye vision improved significantly after 12 weeks of treatment, with higher adherence than that of available treatments. These initial results support the utility of personalized therapy in amblyopia and may have broader relevance for improving treatment outcomes in additional indications.
鉴于治疗依从性差的普遍存在以及医疗保健领域自我报告的偏见，我们假设一种引人入胜的个性化治疗方法可能会改善家庭治疗的依从性和治疗效果。我们在弱视的初始适应证中检验了这一假设，弱视是一种神经发育障碍，其可用的治疗方法因依从性低而受到限制。我们设计了一种新颖的数字治疗方法，可实时将患者选择的电影内容修改为治疗性视觉输入，同时客观监测依从性。治疗设计集成了一个定制的耳机，可将精确的视觉输入传送到每只眼睛，应用实时治疗修改的计算算法，基于云的内容管理系统，可实现家庭治疗，以及广泛的许可内容库。在该治疗方法的概念验证人体研究中，我们发现经过 12 周的治疗，弱视眼的视力显著提高，且依从性高于现有治疗方法。这些初步结果支持个性化治疗在弱视中的应用，并可能对改善其他适应证的治疗效果具有更广泛的意义。
